MCE CARREL is particularly active across the biotech industry, often assisting with investment and commercialisation issues. Alexandra Carrel is noted for her vast knowledge of mandates concerning the manufacturing, production, and distribution of healthcare products, and the negotiation of licence and collaboration agreements. Drawing on her prior expertise within the pharma industry, Mathilde Salavin often advises on clinical trial agreements and commercial partnerships.
Testimonials
Collated independently by Legal 500 research team.
‘Very good listening skills and good understanding of our needs, availability and responsiveness of the team, pragmatic and wise advice in the face of our problems.’
‘Alexandra Carrel is a high-quality partner, and a very good, wise and strategic advisor who knows how to stay on top of her files.’
‘Personalised support directly by a senior, in-depth support on a wide range of contracts (commercial, intellectual property, etc.) as well as on the prevention and management of disputes. Very fluid communication.’
‘Alexandra Carrel stands out for her responsiveness, accessibility, relevance and level of analysis, and range of skills (both in the direct negotiation of licensing agreements with pharma and in the prevention of litigation, contractual issues, legal analysis and advice in the field of HealthTech and medicine). Double registration with the Paris and Geneva bars. Truly remarkable support.’
‘The team has always been fully invested and proactive at our side, especially the management team (Alexandra Carrel in particular).’
‘Alexandra Carrel is a person with rare qualities, strong legal expertise, and knowledge of both French and Swiss law, which is very practical when you negotiate internationally and must offer a neutral jurisdiction. She is a person of great intelligence.’
‘The firm's team works in a coordinated manner to provide the best possible service according to specific requests. Young recruits are very involved. The distribution of tasks according to the different specialties allows for efficient work and the entire firm has excellent relations with other teams in the biotech sector, which allows for particularly effective work during negotiations. Very personal management of cases, young and dynamic team, serious and involved.’
‘Alexandra Carrel has a very in-depth knowledge of the practices of the biotech sector, in addition to being incredibly available for small businesses. Antoine Robin is extremely thorough and available.’
Key clients
- Imcheck
- Egle Therapeutics
- Advesya
- Carthera
- Theradial
- Vect-Horus
- Phost’In
- Biodol
- Emglev
- Superbranche
- ADREP Calym
- LYSARC
- CHU de Nîmes
- UPEC
- Epigene Labs
- Genoscreen
- Everzom
- Gencovery
- Dianosic
- Blackleaf
Work highlights
- Advised Vect-Horus on the negotiation of an exclusive licence agreement with Novo Nordisk to develop targeted therapeutics.
- Advised Vect-Horus on the negotiation of an exclusive licence agreement with Ionis Pharma for the treatment of neurological diseases, with a double digit upfront for Vect-Horus.
- Advised Phost’In on the negotiation of an exclusive licence agreement to exploit Phost’in Therapeutics’s cutting-edge technologies targeting N-glycosylation to bring benefit to oncology and fibrosis patients.
Practice head
The lawyer(s) leading their teams.
Alexandra Carrel, Mathilde Salavin